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Bayer AG v. Schein Pharmaceuticals, Inc.:1 A
Pharmaceutical Company’s Victory in Securing a Patent
Monopoly over Ciprofloxacin2
Glenna L. Gilbert**
In 1980, Dr. Klaus Grohe, a scientist for Bayer, attended a
conference in Japan where the structure of an antibiotic known
as norfloxacin was disclosed.3
From the structure of
norfloxacin, the broad-spectrum antibiotic ciprofloxacin (Cipro)
can be manufactured by a simple substitution of a cyclopropyl
group for an ethyl group.4 With this knowledge in hand, Dr.
Grohe “hastened home from the conference determined to make
such a compound.”5 Despite Dr. Grohe’s efforts, his standard
methodology was unsuccessful in his attempted synthesis of
Cipro.6 He could not construct the starting material needed for
the intermediate chemical reaction.7 Therefore, he called upon
a colleague, Dr. Klauke, who “successfully synthesized the
precursor 2,4-dichloro-5-fluorobenzoyl chloride, the so-called
‘Klauke compound,’ necessary to make [Cipro] via
cycloaracyclation.”8 By using the Klauke compound, Dr. Grohe
was able to synthesize the second intermediate in the synthesis
of Cipro, known as 6-FQA, which he then successfully made
into Cipro.9
* This article is published online at http://mipr.umn.edu.
1. Bayer AG v. Schein Pharm., Inc., 301 F.3d 1306 (Fed. Cir. 2002).
2. “Ciprofloxacin is a relatively simple heterocyclic organic compound
developed by Bayer . . . .” Id. at 1309.
**

JD Candidate 2005, University of Minnesota Law School.

3. Id.
4. See id. Cipro is used to treat a wide variety of bacterial infections in
humans. See CiproUSA at http://www.ciprousa.com/cipro_other/index.asp
(last visited November 5, 2003).
5. Bayer, 301 F.3d at 1309.
6. Dr. Grohe succeeded in making numerous compounds similar in
structure to ciprofloxacin, but failed at making Cipro with his standard
methodology. Id. at 1310.
7. See id.
8. Id.
9. Id.
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In Bayer AG v. Schein Pharmaceuticals, Inc.,10 Bayer AG
and Bayer Corporation, collectively known as “Bayer”, sued five
companies collectively known as “Schein”11 for infringement of
U.S. Patent No. 4,670,444 and Reexamination Certificate B1
4,670,444, collectively known as the “‘444 patent.”12 The ‘444
patent claims a class of compounds that includes Cipro.13
However, the ‘444 patent was not the first filed patent that
claimed Cipro.14 Seven other applications preceded the ‘444
patent, four of which are foreign applications that are relevant
to this case.15
The five defendants16 in this case filed Abbreviated New
Drug Applications (ANDAs) with the FDA, seeking “approval to
market generic versions of [Cipro].”17 These ANDAs led Bayer
to sue Schein for infringement of the ‘444 patent.18 On crossmotions for summary judgment, Schein conceded infringement
of the ‘444 patent but claimed that the ‘444 patent “is invalid
based on the filing and issuance of the Chilean, South African,
Spanish and Argentinean patents,19 because under 35 U.S.C. §
102(d) those foreign patents are prior art that would invalidate
the ‘444 patent.”20 Bayer argued that the ‘444 patent is
10. Id.
11. The five companies are Schein Pharmaceutical, Inc., Danbury
Pharmacal, Inc., Reddy-Cheminor, Inc., Mylan Pharmaceuticals, Inc., and
Mylan Laboratories Inc. Id at 1308.
12. Id.
13. Id. at 1310.
14. Id.
15. Id. at 1310-11. “Bayer filed the first relevant patent application in
Chile on August 12, 1981.” Id. at 1311. The next day, Bayer filed the ‘560
application in the United States, followed by “applications in South Africa
(September 2, 1981), Spain (September 2, 1981), and Argentina (September 3,
1981).” Id. The applications in Chile, South Africa, Spain and Argentina
issued as patents between May and September of 1982. Id. On October 22,
1982, after the issuance of the foreign patents, Bayer filed for a second United
States application, the ‘112 application, as a continuation of the ‘560
application. Id. Bayer subsequently abandoned the ‘560 application. Id.
Bayer then filed a third United States application, the ‘923 application, on
May 29, 1984, as a continuation-in-part of the ‘112 application. Id. The ‘923
application eventually “matured into the ‘444 patent, which [finally] issued on
June 2, 1987.” Id.
16. See supra note 11 and accompanying text.
17. Bayer, 301 F.3d at 1311.
18. See id. “Bayer sued under 35 U.S.C. § 271(e)(2), alleging that filing
the ANDAs infringed the ‘444 patent, and this suit stayed the ANDAs before
the FDA.” Id.
19. See supra note 15 and accompanying text.
20. Bayer, 301 F.3d at 1311.
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entitled to the same filing date as the ‘560 application: August
13, 1981.21 Schein countered by arguing that Bayer could not
rely on the ‘560 application date because that application did
not disclose “Grohe’s best mode of making ciprofloxacin as
required by section 112.”22
In Bayer, the district court granted Bayer’s motion for
summary judgment, holding that “the ‘560 application satisfies
the best mode requirement.”23 Schein subsequently appealed.24
The Federal Circuit affirmed the lower court’s decision.25 The
court held that “[b]ecause the ‘560 application complies with
the disclosure requirements of section 112, the ‘444 patent can
claim the benefit of the ‘560 application’s August 13, 1981,
filing date.”26 Thus, because this date is within one year of the
filing dates of the four foreign patents, the “issuance of
those . . . patents does not invalidate the ‘444 patent under
section 102(d).”27
This Comment argues that, contrary to the Federal
Circuit’s holding in Bayer, the ‘444 patent failed to comply with
§ 112 and violated the best mode requirement when it failed to
disclose fully the synthesis pathways for the precursors to
Cipro.28 The first section of this Comment focuses on the
legislative and case history behind the best mode requirement.
The second section analyzes Bayer in detail, examining each of
the Federal Circuit’s holdings in the case. The final section
then analyzes these holdings in light of the legislative purposes
and case law precedent of the best mode requirement. This
Comment concludes that the Federal Circuit’s decision in Bayer
both does not honor the purpose of the best mode requirement
and does not follow its own precedent in prior cases concerning
the best mode requirement.

21. Id. Bayer alternatively argued “that under 35 U.S.C. § 119, it should
be entitled to the filing date of the second German application, October 29,
1981.” Id. See also supra note 15 and accompanying text.
22. Bayer, 301 F.3d. at 1311.
See also infra notes 34-35 and
accompanying text.
23. Bayer, 301 F.3d. at 1311.
24. Id. at 1312.
25. Id. at 1323.
26. Id.
27. Id.
28. See supra notes 6-9 and accompanying text.
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I. A HISTORICAL PERSPECTIVE OF THE BEST MODE
REQUIREMENT
A. THE BACKGROUND AND PURPOSES OF THE BEST MODE
REQUIREMENT
The United States Constitution grants Congress the power
“[t]o promote the Progress of Science and useful Arts, by
securing for limited Times, to Authors and Inventors, the
exclusive Right to their respective Writings and Discoveries”.29
In response, Congress enacted the Patent Act,30 which grants
successful patentees a monopoly on their invention for a limited
time.31 This monopoly is granted in exchange for the disclosure
of the invention to the public and its eventual entry into the
public domain.32
However, a patent is only granted if the invention satisfies
the substantive and procedural statutory requirements set out
in Title 35 of the United States Code.33 Disclosure is one of
these statutory requirements.34 This requirement is stated as
follows:
The specification shall contain a written description of the invention,
and of the manner and process of making and using it, in such full,
clear, concise, and exact terms as to enable any person skilled in the
art to which it pertains . . . to make and use the same, and shall set
forth the best mode contemplated by the inventor of carrying out his
invention.35

The disclosure requirement ensures that the public
receives information on every essential aspect of the patented
invention.36 Therefore, in essence, the public receives a “quid
29. U.S. CONST. art. I, § 8, cl. 8.
30. Patent Act of 1952, 35 U.S.C. §§ 1-376 (2000).
31. Richard M. Mescher, Patent Law: Best Mode Disclosure—Genetic
Engineers Get Their Trade Secret and Their Patent Too?—Amgen, Inc. v.
Chugai Pharmaceutical Co., 927 F.2d 1200 (Fed. Cir.), cert. denied, 112 S.Ct.
169 (interim ed. 1991), 18 U. DAYTON L. REV. 177, 177 (1992); see also
Christopher S. Marchese, Confusion, Uncertainty, and the Best Mode
Requirement, 2 FED. CIR. B.J. 1, 4-6 (1992) (explaining that the exclusive
rights conferred on an inventor by a patent includes licensing the invention
and suing for infringement when others make, use, or sell the invention).
32. Mescher, supra note 31, at 177.
33. 35 U.S.C. § 101; Mescher, supra note 31, at 177.
34. Patent Act, 35 U.S.C. §112, ¶ 1 (2000).
35. Id. (emphasis added).
36. See Bonita Boats, Inc. v. Thunder Craft Boats, Inc., 489 U.S. 141, 15052 (1989). The Supreme Court stated:
The federal patent system thus embodies a carefully crafted bargain
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pro quo” for granting the monopoly to the inventor.37
In a patent infringement suit, an alleged infringer can
claim inadequate disclosure as a defense if a patent is issued
without proper disclosure.38 The claim of inadequate disclosure
includes the enablement39 and best mode defenses.40 This
comment concerns the best mode requirement,41 which focuses
on an “inventor’s particular embodiment or method of making
the invention.”42
The best mode requirement serves two main purposes.
First, it “assures that the [patent] specification provides
information to the public concerning what the invention is and
how it can be practiced.”43 As Judge Rich explained in In re
Nelson,44 the best mode requirement prevents an inventor from
“disclos[ing] only what he knows to be his second-best
embodiment, retaining the best for himself.” 45 The second
for encouraging the creation and disclosure of new, useful, and
nonobvious advances in technology and design in return for the
exclusive right to practice the invention for a period of years.
. . . We have long held that after the expiration of a federal patent, the
subject matter of the patent passes to the free use of the public as a
matter of federal law.
Id. at 150-52.
37. See supra note 36 and accompanying text; see also Marchese, supra
note 31, at 1 (expounding the purpose of the best mode requirement as
“providing the public with full disclosure of inventors’ innovations in exchange
for the exclusive rights that accompany the grant of a patent, while
simultaneously preventing inventors from selfishly concealing their preferred
embodiments.”) (footnotes omitted); Mescher, supra note 31, at 177 (stating
that the inventor must fully disclose an invention to comply with statutory
requirements).
38. Mescher, supra note 31, at 178 (“[I]f a patent is issued without proper
disclosure it can be invalidated by the courts when an alleged infringer claims
inadequate disclosure as a defense in an infringement suit.”); see also William
F. Herbert, Failure to Disclose the “Best Mode”: What the Public Doesn’t Know
Will Hurt Them, 64 J. PAT. OFF. SOC’Y 12, 25 (1982) (citing failure to disclose
best mode as defense to non-infringement).
39. The purpose of the enablement requirement is to enable those skilled
in the art to make and use the invention. See In re Nelson, 280 F.2d 172, 184
(C.C.P.A. 1960).
40. Mescher, supra note 31, at 178.
41. See infra notes 42-46 and accompanying text.
42. Marchese, supra note 31, at 9.
43. Mescher, supra note 31, at 181 (footnote omitted); see also Herbert,
supra note 38, at 32.
44. In re Nelson, 280 F.2d 172.
45. Id.at 184; see also Gordon T. Arnold, Developing the Evidence on
Patent Validity Issues, in 1 PATENT LITIGATION 1993 509, 536 (Tom Arnold et
al. eds., 1993) (“‘One of the main reasons for the Patent Code is to encourage
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purpose of the best mode requirement is to ensure that the
disclosure of the invention provides the public with information
that encourages current and future research in the “art of the
invention” by the public and competitors.46
B. LEGISLATIVE HISTORY OF 35 U.S.C. §112
Congress adopted the first Patent Act in 1790.47 This act
contained an enablement requirement48 as well as a
requirement for the “whole truth.”49
The “whole truth”
requirement, a forerunner of the best mode requirement,50
formed the basis of the “whole truth” defense of patent
When charged with patent infringement,
infringement.51
Defendants could argue that the specification “‘does not contain
the whole truth concerning his invention,’ or ‘contains more
than is necessary to produce that effect described’ if either
‘appear[ed] to have been intended to mislead, or shall actually
mislead the public, so as the effect described cannot be

inventors to make the necessary disclosures to permit others to advance the
art; inventors may not keep secret information essential for that purpose.’”)
(quoting Imperial Chem. Indus. v. Barr Lab., 22 USPQ2d 1906, 1907 (S.D.N.Y
1992)); Marchese, supra note 31, at 9 (“The best mode disclosure requirement
prevents inventors from selfishly concealing their preferred embodiments,
which are developed before filing the application, thereby retaining the best
for themselves.”) (footnote omitted).
46. Mescher, supra note 31, at 181; see also David Conlin, The Patent
Application, in 2 PATENT PRACTICE 9, at 9-1 to 9-3 (Irving Kayton, ed., 1985)
(listing important functions of the patent application, including “disclosure by
which the public may learn what the invention is and how to practice it when
the patent term expires”); Marchese, supra note 31, at 7 (“Through disclosure,
the patent system introduces new designs and technologies into the public
domain, and thereby increases the public store of knowledge and
information.”).
47. Act of April 10, 1790, ch. 7, 1 Stat. 109-12; Thomas L. Irving et al.,
The Significant Federal Circuit Cases Interpreting Section 112, 41 AM. U. L.
REV. 621, 624 (1992); Marchese, supra note 31, at 10.
48. The enablement requirement in the 1790 Patent Act required patent
applicants to “file a specification describing the applicant’s invention to
distinguish the invention from prior art and ‘to ensure a workman or other
person skilled in [the] art’ could make, build, or use the invention.” Marchese,
supra note 31, at 10 (quoting Act of April 10, 1790, ch. 7, § 2, 1 Stat. 109).
49. Act of April 10, 1790, ch. 7, § 6, 1 Stat. 109. See Marchese, supra note
31, at 10 (stating that the 1790 Act provided “the forerunner of the best mode
requirement” in the form of the whole truth defense that could be asserted in a
patent infringement suit).
50. Marchese, supra note 31, at 10.
51. Act of April 10, 1790, ch. 7, § 6, 1 Stat. 109. See also Irving, supra
note 47, at 624 (for a discussion of the “whole truth” defense).
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produced by the means specified.’”52
In the Act of 1793,53 Congress added the requirement that
applicants of mechanical inventions must “fully explain the
principle, and the several modes in which he has contemplated
the application of that principle.”54
The “best mode” provision superseded the “several modes”
provision in the Patent Act of 1870.55 However, as in the Act of
1793,56 this best mode requirement only applied to machines.57
The relevant section of the 1870 Act “provided that an inventor
‘shall explain the principle [of the machine], and the best mode
in which he has contemplated applying that principle so as to
distinguish it from other inventions.’”58
Finally, in the Patent Act of 1952, the best mode
requirement was expanded to include all inventions59 and the
best mode requirement replaced the whole truth defense.60
Therefore, failure to disclose the invention is now a defense
regardless of intent.61
C. JUDICIAL INTERPRETATION OF THE BEST MODE
REQUIREMENT
1. The Early Cases Before the Establishment of the Federal
Circuit Courts first recognized the purpose of the best mode
requirement in In re Gay.62 The United States Court of
Customs and Patent Appeals declared that the “sole purpose of
[the best mode requirement] is to restrain inventors from
52. Irving, supra note 47, at 624 (quoting Act of April 10, 1790, ch. 7, § 6,
1 Stat. 109) (alteration in orginal).
53. Act of February 21, 1793, ch. 11, 1 Stat. 318-23 (amended 1836).
54. Id. (emphasis added).
55. Irving, supra note 47, at 625 (discussing the 1870 amendments to the
Act of July 8, 1870, ch. 230, §26, 16 Stat. 198, 201).
56. Act of February 21, 1793, ch. 11, 1 Stat. 318-23 (amended 1836).
57. See Marchese, supra note 31, at 12.
58. Id. (quoting Act of July 8, 1870, ch. 230, § 26, 16 Stat. 198, 201)
(alteration in original).
59. Irving, supra note 47, at 626.
60. Marchese, supra note 31, at 13.
61. See Pasquale J. Federico, Commentary on the New Patent Act, 35
U.S.C.A §§ 1-376 (1954), reprinted in 75 J. PAT. & TRADEMARK OFF. SOC’Y
161, 216 (1993) (“Since intention to deceive the public was an element of [the
whole truth] defense it was seldom raised; [therefore] failure to give a
description of the invention as required by Section 112 is a defense without
regard to intention”).
62. In re Gay, 309 F.2d 769 (C.C.P.A. 1962).
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applying for patents while at the same time concealing from the
public preferred embodiments of their inventions which they
have in fact conceived.”63
Another early case which was central to current judicial
interpretations of the best mode requirement is Flick-Reedy
Corp. v. Hydro-Line Manufacturing Co.64 This case concerned a
seal for preventing leakage between the end of a cylinder and
its head,65 and the court determined that “[t]he findings of fact
and the patent specifications and claims ma[d]e clear that an
essential element of the patent [was] the ‘sealing relation’
between the outer machined surface of the reduced thickness at
the end of the tube and the outer surface of the recessed groove
in the head.”66 The court also found that the specification
stated that the outer surface of the reduced thickness section
was made with a special tool.67 Furthermore, this special tool
was not disclosed in the specifications or claims.68 Because of
this nondisclosure, the Seventh Circuit Court of Appeals
upheld the District Court’s holding that the patent was invalid
under 35 U.S.C. § 112.69
The First Circuit Court of Appeals then distinguished
Flick-Reedy in International Telephone & Telegraph Co. v.
Raychem Corp.70 In this case, the patent involved a wire
insulation composed of a primary layer of a cross linked
polyolefin and a secondary, outer layer of cross linked
polyvinylidene fluoride.71 International Telephone & Telegraph
claimed that the patent did not disclose the “precise chemical
formulations” that Raychem used to produce its commercial
wire.72 More specifically, Raychem did not disclose the “use of
two copolymers in the polyethylene layer of the wire insulation”
and “the formula of a secret, proprietary compound” added to

63. Id. at 772.
64. Flick-Reedy Corp. v. Hydro-Line Mfg. Co., 351 F.2d 546 (7th Cir.
1965).
65. Id. at 550.
66. Id.
67. Id.
68. Id.
69. Id. at 551; see also supra notes 34-35 and accompanying text.
70. Int’l Telephone & Telegraph Corp. v. Raychem Corp., 538 F.2d 453,
460 (1st Cir. 1976).
71. Id. at 454.
72. Id. at 459.
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the outer layer.73 Raychem claimed that these omissions did
not violate the best mode requirement since the copolymers and
the secret proprietary compound did not change the qualities of
the finished product.74 Instead, they were used to aid in the
“extrusion of the plastics during the manufacturing process.”75
In response, the First Circuit reiterated its previous
interpretation of the best mode requirement as requiring the
disclosure of “‘specific material[s] which will make possible the
successful reproduction of the effects claimed by the patent.’”76
The court concluded, however, that the undisclosed elements
were not essential to the production of the patented wires; and
therefore the patent was valid against a best mode defense.77
In Flick-Reedy the special tool was essential,78 in International
Telephone the copolymers were not essential to the invention
claimed.79 Thus, the court appeared to make a distinction
between essential materials and nonessential materials,
holding that essential materials must be disclosed in order to
satisfy the best mode requirement.80
2. Cases From the Inception of the Federal Circuit to 1991
The first major best mode case decided by the Federal
Circuit was Christianson v. Colt Industries Operating Corp.81
The court held that the best mode requirement relates to what
is required to practice the claimed invention,82 not what is
required for mass production and sales of the invention to
customers.83 Therefore, after Christianson, a patentee could
73. Id.
74. Id. at 459-60.
75. Id. at 460.
76. Id.(quoting Dale Elec., Inc. v. R.C.L. Elec., Inc., 488 F.2d 382, 389 (1st
Cir. 1973)).
77. Id.
78. See supra notes 64-69 and accompanying text.
79. Int’l Telephone & Telegraph, 538 F.2d at 460.
80. See supra notes 64-79 and accompanying text.
81. Christianson v. Colt Indus. Operating Corp., 822 F.2d 1544 (Fed. Cir.
1987).
82. Id. at 1563.
83. See id. “Christianson accused Colt of violating the best mode
requirement because Colt failed to disclose the tolerances and mass production
data necessary to make the claimed invention (a part for a rifle)
interchangeable in a particular use (the M16).” Arnold, supra note 45 at 565.
The Christianson court stated that “[t]he patent system has conferred on Colt
no exclusivity or economic advantage respecting Colt’s dimensions, tolerances,
and drawings necessary for interchangeability.” Christianson, 822 F.2d at
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not base a best mode violation on unclaimed subject matter
that was necessary for optimal production and sales of the
claimed invention.84
The next major case, Spectra-Physics, Inc. v. Coherent,
Inc.,85 involved two of Coherent’s patents, the Hobart patent,
which is directed to an ion laser structure and the Mefferd
patent, which is directed to a method of fabricating the ion
laser.86 Both patents stress the fact that the bond between the
copper cups and the ceramic tube must be able to withstand
“repeated heat cycling” in order for the laser to be reliable.87 To
make the critical copper-ceramic bond, Wayne Mefferd
developed a six-stage braze cycle involving the use of TitaniumCopper-Silicon (TiCuSil) brazing.88 The patent specification did
identify several techniques for attaching the copper cups to the
ceramic tube including the TiCuSil blazing.89 However, details
of the brazing cycle, were not adequately disclosed in either
patent, nor was it known in the prior art.90 As a result, the
Federal Circuit held that both patents were invalid because
they did not disclose the best mode of carrying out the
invention.91 According to the Federal Circuit, if the patent
applicant “develops specific instrumentalities or techniques
which are recognized at the time of filing as the best way of
carrying out the invention, then the best mode requirement
imposes an obligation to disclose that information to the public
1563.
84. See Christianson, 822 F.2d at 1563; Irving, supra note 47, at 711
(explaining the holding in Christianson).
85. Spectra-Physics, Inc. v. Coherent, Inc., 827 F.2d 1524 (Fed. Cir. 1987).
86. Id. at 1526.
87. Id. at 1529.
88. Id. at 1531 (“Mefferd’s six-stage cycle produced a reliable braze joint
between the copper cups and the ceramic tube. Because this approach worked,
Coherent continued to use TiCuSil and . . . [did not] further experiment[] with
soldering.”).
89. Arnold, supra note 45, at 545.
90. The court stated “[t]he appropriate question then is not whether the
inventors disclosed TiCuSil brazing at all—they did—but whether TiCuSil
brazing was adequately disclosed.”
Spectra-Physics, 827 F.2d at 1536
(emphasis in original). Furthermore, “[e]ven though there may be a general
reference to the best mode, the quality of the disclosure may be so poor as to
effectively result in concealment.” Id. The court then concluded “[t]he facts
found by the district court . . . plainly demonstrate that the TiCuSil brazing
technique used by Coherent was not adequately disclosed.” Id. The court also
noted that “Coherent admits that its braze cycle is not disclosed in either
patent nor is it contained in the prior art.” Id.
91. Spectra-Physics, 827 F.2d at 1538.
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as well.”92
Crucial to the Federal Circuit’s opinion in Spectra-Physics
was the fact that the prior art did not show how to use the
TiCuSil technique that Coherent employed.93 This case “shows
that at least some judges on the Federal Circuit want to see the
disclosure of something more than the preferred structure.”94
Following Spectra-Physics, the Federal Circuit stated in
Randomex, Inc. v. Scopus Corp.:95
Because not complying with the best mode requirement amounts to
concealing the preferred mode contemplated by the applicant at the
time of filing, in order to find that the best mode requirement is not
satisfied, it must be shown that the applicant knew of and concealed a
better mode than he disclosed.96

Therefore, in order to find a best mode violation, it must be
shown that the inventor possessed an undisclosed preferred
embodiment at the time of filing of the patent application.97 In
this case, the court also explained the best mode requirement
in dicta: “if one should invent a new and improved internal
combustion engine, the best mode requirement would require a
patentee to divulge the fuel on which it would run best. This
patentee, however, would not be required to disclose the
formula for refining gasoline or any other petroleum product.”98
Randomex involved a patent for a portable apparatus for
cleaning computer disk packs.99 The court viewed the cleaning
solution “as a fluid for use with the claimed invention,” but “not
as a limiting feature of the claims.”100 The cleaning solution
was not “a part of the ‘essence’ of the invention.”101 In other
words, the cleaning solution was the “fuel” that would run the
disk, or “engine” of the invention.102
In Dana Corp. v. IPC Ltd. Partnership,103 the patent

92. Id. at 1532.
93. Arnold, supra note 45, at 545-46.
94. Id. at 547.
95. Randomex, Inc. v. Scopus Corp., 849 F.2d 585 (Fed. Cir. 1988).
96. Id. at 587 (citing Hybritech Inc. v. Monoclonal Antibodies, Inc., 802
F.2d 1367, 1384-85 (Fed. Cir. 1986)).
97. See id. at 587.
98. Id. at 590.
99. Id. at 586.
100. Arnold, supra note 45, at 554.
101. Id.
102. See supra note 98 and accompanying text.
103. Dana Corp. v. IPC Ltd. P’ship, 860 F.2d 415 (Fed. Cir. 1988).
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claimed a valve stem seal for internal combustion engines.104
The alleged infringer claimed that fluoride treatment of the
rubber for the seal was essential for the valves to seal
properly.105 Since Dana’s patent did not state the fluoride
requirement,106 the infringer asserted the defense that the best
mode requirement was not satisfied.107
Dana countered by submitting an article to the court that
explained that fluoride treatment is known to those skilled in
The Federal Circuit disagreed with Dana’s
the art.108
argument, holding that the “best mode requirement is not
satisfied by reference to the level of skill in the art.”109 Rather,
the best mode requirement “entails a comparison of the facts
known to the inventor regarding the invention at the time the
application was filed and the disclosure in the specification.”110
Therefore, since the established facts showed that fluoride
treatment was the best mode, the patent did not satisfy this
requirement when it failed to make the fluoride disclosure.111
Next, in Chemcast Corp. v. Arco Industries Corp.,112 the
patent claimed a sealing member in the “form of a grommet or
plug button” that was designed to seal an opening in a panel.113
Unlike its previous holding in Dana,114 the Federal Circuit in
Chemcast held that “the disclosure required by section 112 is
directed to those skilled in the art.”115 Therefore, “one must
consider the level of skill in the relevant art in determining
whether a specification discloses the best mode.”116 The court
held there to be a second “objective limitation on the extent of
the disclosure required to comply with the best mode
104. See id. at 416.
105. Id. at 417.
106. See Arnold, supra note 45, at 548 (citing the actual specification).
107. Id.
108. See Dana, 860 F.2d at 418-19 (Fed. Cir. 1988) (stating that Dana
argued the best mode requirement was satisfied because the “fluoride
treatment of Buna-N rubber for seal applications was known to the public [for]
years . . . . A technical article from Rubber Age magazine and certain expert
testimony was cited by Dana as supporting the view that such a treatment
was common to the skilled artisan”). See also Arnold, supra note 45, at 549.
109. See Dana, 860 F.2d at 419.
110. Id.
111. See id. at 420.
112. Chemcast Corp. v. Arco Indus. Corp., 913 F.2d 923 (Fed. Cir. 1990).
113. Id. at 924.
114. See supra notes 103-111 and accompanying text.
115. Chemcast, 913 F.2d at 926 (emphasis added).
116. Id. at 927.
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requirement.”117
The limitation is that the best mode
requirement is restricted to what is claimed in the invention.118
Unlike the holding in Christianson v. Colt119, this time the
Federal Circuit put no parameters on the best mode
requirement.120
Therefore, the court summarized a proper best mode
analysis as having two parts.121 The first component is
“whether, at the time the inventor filed his patent application,
he knew of a mode of practicing his claimed invention that he
considered to be better than any other.”122 This part of the
analysis is entirely subjective.123 The second part of the
analysis “compares what [the inventor] knew with what he
disclosed—is the disclosure adequate to enable one skilled in
the art to practice the best mode or, in other words, has the
inventor ‘concealed’ his preferred mode from the ‘public’?”124
This component is objective, and “depends upon the scope of the
claimed invention and the level of skill in the art.”125
Thus, by employing a two-prong analysis, the court found
the patent in Chemcast invalid.126 The inventor in this case
knew that the preferred material for the locking portion of the
grommet was a “rigid polyvinyl chloride plastisol composition,
having a ‘75 +/-5 Shore D’ hardness.”127 The only compound
fitting this description was a compound known as R-4467.128
However, this compound was not disclosed in the
specification.129 Furthermore, this concealed information was a
preferred ingredient for making an element of the invention,
and therefore involved unclaimed subject matter.130 Therefore,
117. Id.
118. Id.
119. See supra notes 81-84 and accompanying text.
120. See Chemcast, 913 F.2d at 927-28 (Fed. Cir. 1990).
121. Id. at 927.
122. Id. at 928.
123. Id.
124. Id.
125. Id.
126. Id. at 930. See also Northern Telecom, Inc. v. Datapoint Corp., 908
F.2d 931 (Fed. Cir. 1990) (a case involving an inventor who failed to disclose
his preferred embodiment for a specific type of audio tape with different
features than standard audio tapes. The court held the patent to be in
violation of the best mode requirement).
127. Arnold, supra note 45, at 559.
128. Id.
129. See Arnold, supra note 45, at 560 (discussing the actual specification).
130. See id. at 561.
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the Federal Circuit seemed to “adopt a rule that any
information necessary to practice the best mode of carrying out
the claimed invention must be disclosed.”131
As a result of the Federal Circuit’s holdings in the previous
line of cases,132 it could not be assumed that the best mode
requirement is a “synonym for disclosure of the ‘preferred
embodiment’ of the claimed invention.”133 In other words, the
best mode requirement is not limited to the preferred structure,
but may include both the preferred method of making the
invention and the preferred method of using the invention.134
3. Federal Circuit Opinions Since 1991
In Wahl Instruments Inc. v. Acvious Inc.,135 the court held
that the words in 35 U.S.C. § 112 are “not without
ambiguity.”136 Furthermore, the court found that “the term
‘mode’ and the phrase ‘carrying out the invention’ are not
definable with precision.”137
However, the Federal Circuit in Engel Industries, Inc. v.
Lockformer Co.138 held that “[t]he best mode inquiry is directed
to what the applicant regards as the invention, which in turn is
measured by the claims.”139 Furthermore, the court held that
unclaimed subject matter is not subject to the best mode
requirement.140 Therefore, it seems the Federal Circuit has
been inconsistent in determining whether the best mode
requirement is ambiguous.141
Since 1996, the Federal Circuit has found best mode
requirement violations in three cases.142 The first case was
United States Gypsum Co. v. National Gypsum Co.,143 decided

131. See id.
132. See supra notes 81-131 and accompanying text.
133. Arnold, supra note 45, at 538.
134. Id.
135. Wahl Instruments Inc. v. Acvious Inc., 950 F.2d 1575 (Fed. Cir. 1991).
136. Id. at 1579.
137. Id.
138. Engel Indus., Inc. v. Lockformer Co., 946 F.2d 1528 (Fed. Cir. 1991).
139. Id. at 1531.
140. Id.
141. See supra notes 135-40 and accompanying text.
142. Bayer AG v. Schein Pharms. Inc., 301 F.3d 1306, 1316-19 (Fed. Cir.
2002).
143. United States Gypsum Co. v. Nat’l Gypsum Co., 74 F.3d 1209 (Fed.
Cir. 1996).
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by the Federal Circuit in 1996.144 This case involved a
lightweight joint compound.145 The joint compound contained a
silicone-treated perlite known as Sil-42 perlite.146 However, the
patent’s specification did not refer to Sil-42 perlite.147 The
court determined the inventor selected Sil-42 perlite “because it
did not require screening and because it significantly improved
the physical properties of the joint compound.”148 In other
words, the court found that the inventor “believed that Sil-42
perlite was essential to improving the invention; the material
was not selected as a matter of commercial expediency.”149
Further, the court held that disclosure concerning the best
mode of practicing an invention is required under 35 U.S.C. §
112.150 Therefore, the patent was found invalid by the Federal
Circuit for failure to satisfy the best mode requirement.151
In Great Northern Corp. v. Henry Molded Products, Inc.,152
the Federal Circuit held a patent invalid for failure to disclose
the best mode of carrying out the invention when the
specification did not refer to diamonds that were used in the
invention.153 The factual record of the case indicated that, at a
minimum, the supports for large-diameter rolls could not be
produced without the diamonds.154 This fact demonstrated that
the diamonds were critical to practicing the claimed
invention,155 and were therefore required to be disclosed under
section 112.156
In Nobelpharma AB v. Implant Innovations, Inc.,157 the
patent was on a dental implant that was preferably made of
144. Id. at 1209.
145. Id. at 1210. Joint compounds are adhesives used in the construction
of building walls and ceilings to fill and coat the joints between adjacent
gypsum wallboards. Id.
146. Id. at 1211.
147. Id.
148. Id. at 1213.
149. Id. (emphasis added).
150. See id.
151. See id. at 1216.
152. Great N. Corp. v. Henry Molded Prods. Inc., 94 F.3d 1569 (Fed. Cir.
1996).
153. Id at. 1574.
154. Id. at 1572.
155. Id.
156. See id. (holding that the diamonds related to the best mode for
practicing the claimed invention).
157. Nobelpharma AB v. Implant Innovations Inc., 141 F.3d 1059 (Fed. Cir.
1998).

GILBERT

102

12·14·2003 12:14 PM

MINNESOTA INTEL. PROPERTY REVIEW

[Vol. 5:1

titanium and a network of particularly-sized and particularlyspaced micropits.158 These micropits allow a secure connection
to form between the implant and the growing bone159 in a
process known as osseointegration.160 The patent neglected to
mention a variety of machining parameters that were critical to
the production of a functional dental implant.161 Therefore, the
Federal Circuit held that the patent did not satisfy the best
mode requirement.162
Finally, Eli Lilly & Co. v. Barr Laboratories, Inc.163
involved a pharmaceutical manufacturer of an antidepressant
drug (commercially known as Prozac).164 The patent in this
case disclosed the compound fluoxetine hydrochloride, the
active form of the drug, but did not disclose the inventor’s
preferred method for synthesizing the starting material, ptrifluoromethylphenol,165 necessary to synthesize the drug.166
The Federal Circuit held that an inventor need not disclose a
mode for obtaining unclaimed subject matter unless the
“subject matter is novel and essential for carrying out the best
mode of the invention.”167
The court found that Lilly did disclose the preference for
using p-trifluoromethylphenol when making fluoxetine
hydrochloride.168 However, they also found that Lilly did not
disclose the unclaimed method for synthesizing the starting
material.169 The court went on to hold that “[t]o be sure, if the
best mode for carrying out a claimed invention involves novel
subject matter, then an inventor must disclose a method for
obtaining that subject matter even if it is unclaimed.”170 This
poses a potential problem however because matter disclosed in
the specification but not claimed is given to the public and
therefore cannot be claimed later.171 Nevertheless, in this case,
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168.
169.
170.
171.

Id. at 1062.
Id.
Id.
Id. at 1065.
See id. at 1066.
Eli Lilly & Co. v. Barr Labs. Inc., 222 F.3d 973 (Fed. Cir. 2000).
Id. at 973.
Id. at 978-79.
See id. at 977.
Id. at 981.
Id. at 982.
Id.
Id.(emphasis added).
See Johnston & Johnston Assoc., Inc. v. R.E. Service Co., Inc., 285
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the court held that the record demonstrated that the starting
material was not novel.172 This was based on the fact that the
starting material actually was commercially available.173
Furthermore, the record included prior art references that
showed how to prepare the starting material in fluoxetine
hydrochloride.174
D. UNITED STATES PATENT AND TRADEMARK OFFICE’S
INTERPRETATION OF THE BEST MODE REQUIREMENT
The first step that a patent examiner from the United
States Patent and Trademark Office (USPTO) must follow is to
determine how the invention is defined in the claims.175 Under
the Rules of Examination, the specification “need not set forth
details not relating to the essence of the invention.”176 In other
words, unclaimed subject matter that is not related to the
operation of the invention is not required under the best mode
requirement.177 However, if the patent applicant “develops
specific instrumentalities or techniques which are recognized
by the applicant at the time of filing as the best way of carrying
out the invention, then the best mode requirement imposes an
obligation to disclose that information to the public as well.”178
The examiner should then assume that the best mode is
disclosed in the application, unless evidence is presented that
proves otherwise.179 Furthermore, the patent examiner should
follow the two-prong best mode analysis set out in Chemcast.180
Only evidence of concealment is to be considered in
determining the adequacy of a best mode disclosure.181 This
concealment can either be intentional or accidental.182 This
evidence of concealment must “tend to show that the quality of
an applicant’s best mode disclosure is so poor as to effectively

F.3d 1046, 1051 (Fed. Cir. 2002).
172. See Eli Lilly, 222 F.3d at 982.
173. Id.
174. Id.
175. MANUAL OF PATENT EXAMINING PROCEDURE § 2165.01 (2003)
[hereinafter MANUAL].
176. Id.
177. Id.
178. Id at § 2165.02.
179. Id. at § 2165.03.
180. See id.; see also supra notes 120-26 and accompanying text.
181. See MANUAL, supra note 175, at § 2165.04.
182. See id.
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result in concealment.”183
In conclusion, Congress has extensively dealt with the best
mode requirement through several acts leading up to the
Furthermore, the courts have
Patent Act of 1952.184
interpreted the best mode requirement at length since
Congress established the Patent Act in 1952.185 In light of this
legislative history and judicial precedent, the Federal Circuit
decided Bayer v. Schein.186
II. THE FEDERAL CIRCUIT’S RESOLUTIONS IN BAYER V.
SCHEIN
A. THE BACKGROUND HOLDINGS OF THE FEDERAL CIRCUIT
The Federal Circuit decided Bayer v. Schein on August 9,
2002.187 The court first described the basis for Schein’s
assertion of Bayer’s patent invalidity under 35 U.S.C.
§102(d).188 Section 102(d) provides in relevant part:
A person shall be entitled to a patent unless . . . the invention was
first patented or caused to be patented, or was the subject of an
inventor’s certificate, by the applicant . . . in a foreign country prior to
the date of the application for patent in this country on an application
for patent or inventor’s certificate filed more than twelve months
before the filing of the application in the United States .189

Schein made two allegations in support of invalidity under
section 102(d). First, Schein argued that Bayer filed foreign
patent applications on Cipro more than one year prior to
October 22, 1982.190 October 22, 1982 was the earliest priority
date of the ‘923 application that issued as the ‘444 patent.191
Second, the foreign patent applications issued before October
22, 1982.192 Therefore, the ‘444 patent was filed more than one
year after the filing of the foreign patents and is invalid under
section 102(d), unless Bayer can rely upon an earlier filing

183.
184.
185.
186.
187.
188.
189.
190.
191.
192.

Id.
See supra notes 47-61 and accompanying text.
See supra notes 62-174 and accompanying text.
Bayer AG v. Schein Pharm, Inc., 301 F.3d 1306 (Fed. Cir. 2002).
Id. at 1306.
See id. at 1312.
Id. at 1312 (quoting 35 U.S.C. § 102(d) (2000)).
See id. at 1312-13.
Id.
Id.
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date.193
However, Bayer countered that the ‘444 patent is not
invalid under section 102(d) because the ‘444 patent can claim
priority to the filing date of the ‘560 application under 35
U.S.C. § 120.194 Section 120 provides in relevant part:
An application for patent for an invention disclosed in the manner
provided by the first paragraph of section 112 of this title in an
application previously filed in the United States, . . . which is filed by
an inventor or inventors named in the previously filed application
shall have the same effect, as to such invention, as though filed on the
date of the prior application, if filed before the patenting or
abandonment or termination of proceedings on the first
application.195

Bayer argued that under section 120, the ‘444 patent can claim
priority to August 13, 1982, the filing date of the ‘560,
application,196 Since this date is within a year of the filing date
of the foreign patents, Bayer argued that 102(d) should not
apply.197 However, the court stated that section 120 only
applies if the earlier application fulfills the disclosure
requirements of 35 U.S.C. § 112.198 Therefore, “Bayer may
defeat the 102(d) bar . . . only if the ‘560 application fulfills the
disclosure requirements of section 112.”199
Schein argued that the ‘560 application did not satisfy 35
U.S.C. § 112 because it failed to disclose the best mode
contemplated by Dr. Grohe for making Cipro.200 According to
Schein, the application failed to do so because it did not
“disclose the synthesis of the Klauke compound or the use of
the cycloaracyclation reaction to make 6-FQA.”201 However,
both of these compounds are intermediates which are not
claimed in the ‘444 patent.202 Nevertheless, Schein asserted
that 6-FQA and its synthesis via cycloaracyclation of the
Klauke compound is novel and therefore the preferred method
of making them is required to be disclosed under section 112 in
order to adequately describe the best mode of synthesizing
193.
194.
195.
196.
197.
198.
199.
200.
201.
202.

Id. at 1313.
Id.
Id. (quoting 35 U.S.C. § 120 (2000)).
Id. at 1313.
See supra note 15.
Bayer, 301 F.3d at 1313.
Id.
Id.
Id; see also supra notes 5-10 and accompanying text.
Bayer, 301 F.3d at 1313.
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Cipro.203
In its analysis, the Federal Circuit stated, “compliance
with the best mode requirement requires disclosing the
inventor’s preferred embodiment of the claimed invention.”204
In addition, the court stated, “cases examining the scope of the
best mode requirement demonstrate that the best mode
disclosure requirement only refers to the invention defined by
the claims.”205 Finally, the Federal Circuit held that the
“existence of a best mode is a purely subjective matter
depending upon what the inventor actually believed at the time
the application was filed . . . . [Therefore], the best mode
requirement . . . cannot be met by mute reference to the
knowledge of one of skill in the art.”206
Furthermore, the court found that the best mode
requirement does not “demand disclosure of every preference
an inventor possesses as of the filing date . . . .”207 The Federal
Circuit explained that “[a]s is always the case, the text of the
statute provides the proper boundaries of the disclosure
requirement.”208 The court went on to hold that “[s]ection 112
only demands disclosure of ‘the best mode contemplated by the
inventor of carrying out his invention.’”209
Nevertheless, the court admitted that it has “‘found
violations of the best mode requirement for failure to disclose
subject matter not strictly within the bounds of the claims.’”210
The court found that there had been seven occasions in the
history of the Federal Circuit and its predecessor courts when
patents had been invalidated for failure to meet the best mode
requirement.211 The court found that these cases “involved
either failure to disclose a preferred embodiment, or else failure
to disclose a preference that materially affected making or
using the invention.”212
203. Id. (drawing on the holding in Eli Lilly, 251 F.3d at 964 (Fed. Cir.
2001). See also supra note 170 and accompanying text.
204. Bayer, 301 F.3d at 1316 (emphasis added).
205. Id. at 1315.
206. Id. at 1314.
207. Id. at 1314-15.
208. Id. at 1315.
209. Bayer, 301 F.3d at 1315 (quoting 35 U.S.C. § 112 (1994)) (alteration in
original).
210. Id. at 1316 (quoting Teleflex, Inc. v. Ficosa N. Am. Corp., 299 F.3d
1313, 1331 (Fed. Cir. 2002)).
211. Id.
212. Id.
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B. THE CASE ANALYSES OF THE FEDERAL CIRCUIT IN BAYER V.
SCHEIN
The first case discussed by the Federal Circuit was
Spectra-Physics.213 The Federal Circuit stated that although
the patent specification at issue in Spectra-Physics disclosed
the preference for using TiCuSil as a brazing material, it did
not disclose the parameters for performing the TiCuSil brazing
Since the patent
cycle developed by the inventor.214
specification stressed the importance of brazing in obtaining
efficiency and reliability of the claimed laser, the “failure to
disclose the actual method of brazing preferred by the inventor
rendered the patent claims invalid for ‘failure to disclose the
best mode contemplated by the inventors for practicing
their . . . inventions.’”215
The Federal Circuit then discussed Dana Corp.216 In this
case, the invention was a valve stem seal for an internal
combustion engine.217 The inventor found that a 60-second
fluoride surface treatment was necessary for the seal to
function without leaking.218 According to the Federal Circuit,
“the undisclosed fluoride surface treatment had a material
effect on the properties of the claimed invention.”219 Since “the
inventor ‘believed that the best way of carrying out his
invention included fluoride treating the surface of the valve
seals,’” and the “specification never ‘disclosed that a fluoride
treatment must or even should be applied’ . . . as preferred by
the inventor,” the patent was held to be invalid for failure to
disclose the best mode.220
Next, the court discussed Northern Telecom.221 In this case,
the defendant raised a best mode challenge to claims directed
to capturing data on magnetic tape cassettes.222 The inventor
preferred certain audio tapes with specific yield strength and
magnetic characteristics which were different from standard
213. Id.
214. Id. at 1316. See supra notes 85-94 and accompanying text.
215. Bayer, 301 F.3d at 1316-17 (quoting Spectra-Physics, Inc. v. Coherent,
Inc., 827 F.2d 1524, 1537 (Fed. Cir. 1987)).
216. Id. at 1317. See supra notes 103-11 and accompanying text.
217. Bayer, 301 F.3d at 1317.
218. Id. at 1317.
219. Id.
220. Id. (quoting Dana Corp. v. IPC Ltd. P’ship, 860 F.2d at 419-20).
221. Id. See supra text accompanying note 126.
222. Bayer, 301 F.3d at 1317.
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audio tapes.223 The specification however disclosed neither the
inventor’s specifications for the preferred tape nor the identity
of the brand on the market that met the inventor’s
specifications.224 The court held the patent in violation of the
best mode requirement because the “inventor had developed a
preferred embodiment of his invention that used a very specific
type of audiotape, and failure to disclose that preferred
embodiment . . . .”225
The fourth case discussed by the Federal Circuit is
Chemcast.226 In this case, the claim was directed to a grommet
and the inventor had a preference for a particular material for
making the locking portion of the grommet.227 The patent’s
disclosure was found to be deficient for failure to disclose this
In concealing the preferred
fact in the specification.228
embodiment, the best mode requirement was not satisfied, and
the claims were invalid229
The fifth case discussed by the Federal Circuit in Bayer is
Gypsum.230 Gypsum dealt with the validity of a claim directed
to a compound that contained an “expanding perlite.”231 The
court stated that the inventor “‘believed that Sil-42 perlite was
essential to improving the invention; the material was not
selected as a matter of commercial expediency.’”232 Therefore,
by not disclosing the Sil-42 perlite, the patent did not disclose
the best mode of carrying out the inventor’s preferred
embodiment, and was thus held invalid.233
The Federal Circuit also discussed Great Northern Corp.234
In this case, the patent specification failed to disclosed diamond
indentations that were “crucial to producing a usable version of
the invention.” because without them, the support, “simply
collapsed under the weight of the rolls it was supposed to

223. Id.
224. Id.
225. Id.
226. Id. See supra notes 112-31 and accompanying text.
227. Bayer, 301 F.3d at 1317.
228. Id.
229. Id.
230. Id. See supra notes 142-51 and accompanying text.
231. Bayer, 301 F.3d at 1318.
232. Id. (emphasis added) (quoting United States Gypsum Co. v. Nat’l
Gypsum Co., 74 F.3d 1209, 1213 (Fed. Cir. 1996)).
233. See id. at 1318.
234. Id. See supra notes 152-56 and accompanying text.
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hold.”235 The claims were held to be invalid because the
diamonds that materially affected the properties of the claimed
invention were not disclosed and resulted in a failure to satisfy
the best mode requirement.236
Lastly, the Federal Circuit discussed Nobelpharma.237 In
this case, the patent claimed “an element intended for
implantation in to bone tissue” that contained micropits.238
The production of the implant depended decisively on a number
The undisclosed
of undisclosed machine parameters.239
parameters were said to be “related to manufacture of the
claimed implant, and were critical to production of a functional
Since the undisclosed preference materially
implant.”240
affected the properties of the invention, failure to disclose it
resulted in a violation of the best mode requirement.241
C. ACCORDING TO THE FEDERAL CIRCUIT, BAYER DID NOT
VIOLATE THE BEST MODE REQUIREMENT IN ITS ‘560 PATENT
According to the Federal Circuit, the first step in any best
mode analysis is to identify the invention recited in the
claims.242 The Federal Circuit noted that the claims of the ‘444
patent involve “compositions of matter that either comprise or
consist solely of the target antibiotic compound—in this case
ciprofloxacin.”243 Furthermore, the court noted that the claims
do not recite 6-FQA or any other starting material.244 Thus,

235. Bayer, 301 F.3d at 1318.
236. Id.
237. Id. See supra notes 157-62 and accompanying text.
238. Bayer, 301 F.3d at 1318.
239. Id.
240. Id. at 1318-19.
241. Id. at 1319.
242. See id. at 1320 (discussing N. Telecom Ltd. v. Samsung Elec. Co., 215
F.3d 1281, 1286-87 (Fed Cir. 2000)). Bayer described the holding in N.
Telecom as follows:
[T]he first step in a best mode inquiry, before application of the
familiar two-part best mode test, must be to define the invention by
construing the claims. Definition of the invention ‘is a legal exercise,
wherein the ordinary principles of claim construction apply.’ Defining
the invention by analyzing the claim language is a crucial predicate to
the factual portions of the best mode inquiry because it ensures that
the finder of fact looks only for preferences pertaining to carrying out
the claimed invention.
Id. (emphasis in original) (quoting N. Telecom, 215 F.3d at 1286-87).
243. Id.
244. Id. at 1321.
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“the invention . . . consists of the final antibiotic product and
not the starting materials.”245 In addition, the court noted that
the inventor had a preferred method of making ciprofloxacin by
“manipulating 6-FQA by reacting it with piperazine.”246
Furthermore, the ‘560 application did not disclose either the
Klauke compound or its use in making 6-FQA, which are both
intermediate steps in the synthesis of Cipro.247
However, the Federal Circuit held that Bayer’s failure to
disclose Dr. Grohe’s preferred method of making 6-FQA was
not a violation of the best mode requirement.248 The court
stated that only “[p]references that are reflected in a preferred
embodiment or that relate to making or using the invention
and have a material effect on the properties of the claimed
invention” are required to be disclosed.249 The court found that
failure to disclose the method of making 6-FQA was not fatal
because it had no material effect on the properties of Cipro.250
As a result, the court found this case “clearly distinguishable
from the four cases in which this court has found a best mode
violation where an undisclosed preference clearly had a
material affect on the properties of the claimed invention.”251
Schein raised the argument that disclosure of Dr. Grohe’s
preferred method of producing 6-FQA is mandatory because it
is novel.252 Schein based this contention on the Federal
Circuit’s holding in Eli Lilly.253 However, the court held that
Schein misunderstood the Federal Circuit’s holding in Eli
Lilly.254 The court in Bayer explained that the Federal Circuit
in Eli Lilly “merely acknowledged that when a novel compound
is necessary to practice the best mode, one of skill in the art
must be able to obtain that compound.”255 Therefore, the
245. Id.
246. Id.
247. Id.
248. See id. at 1323.
249. Id. at 1321.
250. See id. at 1321-22.
251. Id. These four cases are Spectra-Physics, Nobelpharma, Dana, and
Great Northern. See supra section II.B.
252. Bayer, 301 F.3d at 1322.
253. Id; see supra notes 163-74 and accompanying text.
254. Bayer, 301 F.3d at 1322 (“Schein understands Eli Lilly to stand for the
proposition that the best mode of obtaining novel subject matter necessary to
practice the invention must be disclosed. Schein has misunderstood the
impact of our statements in Eli Lilly”).
255. Id. at 1322.
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following statements in Eli Lilly, such as “a method for
obtaining that subject matter” and “a mode for obtaining
unclaimed subject matter” refer only to a requirement that the
best mode be enabled by the specification.256 Since the ‘560
patent contains an enabling disclosure of 6-FQA, it complies
with the holding in Eli Lilly as interpreted by the Federal
Circuit.257
In conclusion, the Federal Circuit held in Bayer that Dr.
Grohe’s preferred method of making 6-FQA does not materially
affect the production of Cipro.258 Therefore, its disclosure is not
required to comply with the best mode requirement.259 Since
the ‘560 application is in compliance with 35 U.S.C. §112,
paragraph 1, the ‘444 patent can claim the filing date of the
‘560 application under 35 U.S.C. §120.260 Moreover, because
this filing date is well within the filing date of the first foreign
patent, the issuance of those foreign patents does not invalidate
the ‘444 patent under 35 U.S.C. §102(d).261
III. WHY THE COURT ERRED IN BAYER V. SCHEIN
In Bayer, the Federal Circuit stated that 35 U.S.C. § 112
demands disclosure of the best mode the inventor contemplated
for carrying out the invention.262 The court noted it had held
that nondisclosure of unclaimed subject matter violated the
best mode requirement when the specification failed to disclose
a preferred embodiment or else failed to disclose a preference
that materially affected making or using the invention.263 The
court subsequently held in the instant case that the ‘560 patent
from which the ‘444 patent claimed benefit did not violate the
best mode requirement, because the unclaimed subject matter
did not materially affect making or using the claimed invention
nor was it a preferred embodiment of the claimed invention.264

256.
257.
258.
259.
260.
261.
262.
263.
264.

Id.
See id. at 1323.
See id.
See id.
See id.
Id.
Id. at 1315.
See id. at 1316.
See id. at 1323.
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A. THE KLAUKE COMPOUND AND 6-FQA MATERIALLY AFFECT
THE PRODUCTION OF CIPRO
Analysis of the facts shows that the Klauke compound
materially affected and was vital to the final synthesis of Cipro.
Grohe’s initial method of synthesizing 6-FQA was
unsuccessful.265 The Klauke compound was the only structure
known by Grohe that could be used to synthesize 6-FQA.266 As
such, without the Klauke compound, 6-FQA was an obscurity to
Dr. Grohe and without 6-FQA, the synthesis of Cipro would
Therefore, the Klauke
have been impossible for him.267
compound and the preferred synthetic route to 6-FQA by Grohe
were essential to the production of Cipro. Since essential steps
in a process materially affect the final production of a product,
these two properties of the final invention should have been
disclosed in the specification in order to satisfy the best mode
requirement as interpreted by the Federal Circuit in Bayer.268
The Federal Circuit looked to several cases to support its
holding that the ‘560 patent did not violate the first prong of
the best mode requirement.269 These cases are outlined in
sections I and II of this Comment. Like Bayer, these cases all
involved unclaimed subject matter in the specification.270
However, unlike Bayer, the Federal Circuit found best mode
violations in every one by holding that the unclaimed subject
matter materially affected the claimed invention.271 In Bayer,
the court erred by not finding a direct correlation between the
facts of those cases and the facts in Bayer.
The facts of Spectra-Physics are essentially the same as the
facts of Bayer.272 Both cases involved a certain method that
was optimal for ultimately producing the claimed invention.273
In Spectra-Physics, the inventor had a preferred method for
utilizing the TiCuSil brazing material.274 In Bayer, it was the
use of the Klauke compound and the synthetic pathway of 6-

265.
266.
267.
268.
269.
270.
271.
272.
273.
274.

Id. at 1310.
See id.
See id.
See supra notes 135-74 and accompanying text.
See supra notes 213-61 and accompanying text.
See supra notes 213-41 and accompanying text.
See supra notes 213-41 and accompanying text.
See supra notes 85-94, 187-212 and accompanying text.
See supra notes 85-94, 187-212 and accompanying text.
See supra note 88 and accompanying text.
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FQA.275 In Spectra-Physics, the Federal Circuit made a clear
holding that would directly support a best mode violation by
Bayer – if the patent applicant develops specific
instrumentalities or techniques which are recognized as the
best way of carrying out the invention, the best mode
requirement demands disclosure of the preference.276
Therefore, the Federal Circuit did not make an adequate
comparison between Spectra-Physics and Bayer, applying
Spectra-Physics incorrectly to the facts of Bayer. Clearly, the
Klauke compound is a specific compound (instrumentality)
developed by Bayer to synthesize Cipro. Furthermore, the
Klauke compound is the best way, if not the only way, of
ultimately carrying out the claimed invention.277 Therefore,
according to the Federal Circuit’s logic in Spectra-Physics,
Bayer violated the best mode requirement of 35 U.S.C. § 112.
The Federal Circuit also erred in its analysis of Bayer in
relation to Dana Corp.278 In Dana, a fluoride treatment was
necessary in order for the valve to work properly.279 Thus, the
treatment materially affected the claimed invention. In Bayer,
the Klauke compound was necessary for the synthesis of 6FQA, which was in turn essential to the production of the
This was exactly like the
claimed invention, Cipro.280
undisclosed fluoride treatment in Dana. Therefore, when the
court compared the facts in Bayer to the facts and holding in
Dana, it should have found that Bayer violated the best mode
requirement.
The Federal Circuit also erred in its analysis of Bayer in
In Great Northern,
relation to Great Northern Corp.281
diamond indentations used to stabilize the molded pulp roll
support were crucial to producing a workable version of the
invention.282 Without their disclosure, the Federal Circuit held
that Great Northern’s patent failed the best mode requirement,
because the diamond indentations materially affected the
claimed invention.283 The Klauke compound and the synthetic
275.
276.
277.
278.
279.
280.
281.
282.
283.

See supra notes 268-70 and accompanying text.
See supra note 92 and accompanying text.
See supra notes 265-68 and accompanying text.
See supra notes 216-20 and accompanying text.
See supra notes 218-19 and accompanying text.
See supra notes 265-68 and accompanying text.
See supra notes 234-36 and accompanying text.
See supra notes 234-36 and accompanying text.
See supra notes 234-36 and accompanying text.
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route are the “diamond indentations” of Bayer. Without these
parts of the claimed invention, there would be no usable
version of Cipro. Thus, the court should have also found a best
mode violation in Bayer when comparing the facts of this case
to Great Northern.
Finally, in Nobelpharma, the court found a best mode
violation when the inventor failed to disclose a subjective
preference in the production of the claimed invention, a dental
implant.284 The patentee failed to disclose a variety of specific
machining parameters required in order to produce a
functional implant.285 By analogy, the Klauke compound and
synthesis of 6-FQA are the undisclosed “machining
parameters” required to produce Cipro. Therefore, just as the
parameters in Nobelpharma materially affected the claimed
invention, the Klauke compound and 6-FQA synthesis
materially affect Cipro.
B. THE KLAUKE COMPOUND IS A PREFERRED EMBODIMENT OF
CIPRO
In Northern Telecom, the Federal Circuit found a best
mode violation because a preferred embodiment of the claimed
invention used a specific type of audiotape, which was not
disclosed in the specification 286 The court in Bayer did not
appreciate the relationship between these two cases. The
Klauke compound was a specific precursor to the synthesis of 6FQA.287 Dr. Grohe’s standard method of synthesizing bicyclics
involved beginning with a starting material.288
He was
unsuccessful in producing the material needed for 6-FQA and
enlisted the help of a colleague.289 This method involved the
specific use of the Klauke compound to synthesize 6-FQA.290 It
is undisputed that Dr. Grohe had a preference prior to August
13, 1981, for a class of starting materials including the Klauke
compound.291 Therefore, the court once again should have
found a best mode violation, because the Klauke compound was
a specific, preferred embodiment of the claimed invention.
284.
285.
286.
287.
288.
289.
290.
291.

See supra notes 237-241 and accompanying text.
See supra notes 237-241 and accompanying text.
See supra notes 221-25 and accompanying text.
See Bayer, 301 F.3d at 1310.
See id.
See id.
See id.
Id. at 1321.
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C. BAYER IN LIGHT OF THE POLICY OF THE BEST MODE
REQUIREMENT
The disclosure requirement set out in 35 U.S.C. § 112
ensures that every essential aspect of the invention is made
public with the granting of the patent.292 The entry of the
information into the public domain is essential to promoting
the sharing and expansion of knowledge and the benefits that
flow there from. In the scientific community, for example,
scientists
share
knowledge
through
journals
and
correspondence with one another.
This dissemination of
information advances the progress of science–one scientist
builds on the research and discoveries of another scientist and
so forth. In a similar way, progression of knowledge flows from
patented inventions–one inventor builds on a preceding
inventor’s discoveries, thus advancing science, technology, and
ultimately society.
In Bayer, disclosure of the intermediates in the synthesis of
Cipro was not required according to the Federal Circuit.293
Without their disclosure, however, the public is unaware of how
to make Cipro according to Dr. Grohe’s preferred embodiment.
This lack of disclosure may seem harmless if one assumes most
individuals in society are unlikely to synthesize Cipro.
However, pharmaceutical companies and scientists are also
deprived of the pathway for the synthesis of 6-FQA from the
Klauke compound. If these two entities were granted this
knowledge by its disclosure in the ‘560 patent’s specification,
they might have been able to build on the knowledge of Bayer
and synthesize new and improved antibiotics or other drugs.
Thus, what may seem harmless at first could have heavy
societal consequences.
D. BAYER IN LIGHT OF PRECEDENT
The courts early on recognized the social policy of the best
mode requirement and recognized a quid pro quo status
between patentee and the public.294 In In re Gay, the United
States Court of Customs and Patent Appeals held that a
patentee might not be allowed to conceal an embodiment of his
invention from the public in order to retain possible future

292. See supra notes 34-38 and accompanying text.
293. Bayer, 301 F.3d at 1323.
294. See supra notes 62-63 and accompanying text.
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benefits from such withholding.295 Therefore, as early as 1962,
the courts recognized the quid pro quo between patentee and
the public. The court determined that the patent system, in
addition to spreading knowledge that advances science and
technology, sets up a social hierarchy between the patentee and
the public. The patentee will be granted a limited patent upon
one fundamental consideration–furnishing the public with the
means to reproduce the invention at a later time. The best
mode requirement is a vital aspect of this exchange between
the patentee and public, because it ensures that the public will
be equipped with the inventor’s preferred method of producing
the invention. The hope is that the public will eventually be
able to reproduce the invention with the same amount of effort
as the inventor.
As applied to Bayer, this judicial interpretation of policy
behind the best mode requirement should have resulted in a
holding that invalidated Bayer Corp’s patent for failure to
disclose the Klauke compound and the pathway to synthesis of
6-FQA. Without this disclosure, the public is not granted quid
pro quo. Bayer reaps the benefits of its patent monopoly, but
the public is not furnished with complete knowledge to produce
Cipro after Bayer’s patent monopoly expires. Thus, the social
hierarchy set up by 35 U.S.C. § 112 fails in practice.
The courts have also been deliberate in differentiating
between essential and non-essential elements in their
requirements for patent disclosure. For example, in Randomex,
a pivotal case in best mode jurisprudence, the Federal Circuit
made a concrete distinction between those essential aspects of
an invention that require disclosure and non-essential ones
that do not, explaining that a patentee of an internal
combustion engine would, for example, be required to disclose
the fuel on which the engine runs because it is essential to the
invention.296 However, under the best mode requirement, the
patentee would not be required to disclose the process for
refining fuel because it is not essential to the engine.297 To the
extent that the engine has fuel to run as envisioned, it is
irrelevant how the fuel was produced.298
Cases prior to Randomex also expressed this distinction

295.
296.
297.
298.

See In re Gay, 309 F.2d 769, 774 (C.C.P.A. 1962).
See supra notes 95-97 and accompanying text.
See supra note 98 and accompanying text.
See supra notes 98-102 and accompanying text.
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between essential embodiments of an invention and expendable
ones. In Flick-Reedy, the court found a special tool used to
create the unique seal that was an essential element of the
patent also to be indispensable element of the claimed
invention.299 Therefore, its disclosure was required in order to
satisfy the best mode requirement.300
In International
Telephone the court again made this distinction, however here
it found the undisclosed elements to be nonessential to the
production of the invention, and their disclosure was not
required.301
In Bayer, the Klauke compound and synthesis of 6-FQA
upon which the production of Cipro depends and from which it
is synthesized can be analogized to the fuel of Randomex and
the special tool of Flick-Reedy. Without these two compounds,
Cipro would not exist as synthesized under Dr. Grohe.302 These
two intermediates of Cipro are needed for its efficient
production; therefore they must be disclosed under the Federal
Court’s analyses and holdings in Randomex, Flick-Reedy, and
International Telephone and its articulation of the essential
element requirement.303
The Federal Circuit has articulated further broad
circumstances when information must be disclosed.
In
Chemcast, in addition to establishing the two-prong analysis
that the Federal Circuit currently follows,304 the court further
held that any information necessary to practice the best mode
of the invention must be disclosed.305 This holding is simply
another way of stating the distinction made in Randomex. In
Chemcast, the patentee did not disclose a preferred ingredient
for making an element of the invention and the court held that
the best mode requirement was not satisfied.306 Likewise, in
Bayer, the patentee failed to disclose a preferred ingredient–the
Klauke compound necessary to make an element of the
intermediate, 6-FQA.307 Under the Federal Circuit’s precedent
in Chemcast, Bayer violated the best mode requirement.
299.
300.
301.
302.
303.
304.
305.
306.
307.

See supra notes 64-69 and accompanying text.
See supra notes 64-69 and accompanying text.
See supra notes 70-80 and accompanying text.
See supra notes 296-301 and accompanying text.
See supra note 296 and accompanying text.
See supra notes 112-25 and accompanying text.
See supra note 131 and accompanying text.
See supra notes 127-30 and accompanying text.
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Finally, in United States Gypsum, the Federal Circuit held
that in addition to the disclosure of essential aspects of the
claimed invention, disclosure of the best mode of practicing an
invention is required under 35 U.S.C. § 112.308 Thus, the court
interpreted the text of the best mode requirement as requiring
disclosure of methods of producing or bringing the claimed
invention to fruition. In Bayer, the method of practicing the
claimed invention was to use the Klauke compound to produce
6-FQA and then to use 6-FQA to synthesize Cipro.309 This was
the best mode of practicing the claimed invention as conceived
by Dr. Grohe at the time of patent application.310 Therefore, its
disclosure is required according to Gypsum and the text of 35
U.S.C. § 112.
E. 35 U.S.C. § 112 MAY NOT PERTAIN ONLY TO CLAIMED
SUBJECT MATTER
The Federal Circuit in Bayer held that 35 U.S.C. § 112
“only demands disclosure of ‘the best mode contemplated by the
inventor of carrying out his invention.’”311 However, the court
previously found the phrase “carrying out his invention” in §
112 ambiguous.312 In Wahl Instruments, the court found that
the phrases “mode” and “carrying out the invention” were not
However, a second judicial
precisely definable.313
interpretation held that the phrase applied only to the claimed
invention.314 The first case to address the issue of whether the
best mode requirement is limited to the claimed invention was
Christianson.315 However, this decision was made in reference
to mass production and sales to customers only.316 Therefore, it
was a limited holding that has gained widespread recognition
in the Federal Circuit as binding law in a variety of cases that
do not involve mass production or sales to customers.
Therefore, since the phrases “carrying out the invention”
and “mode” are ambiguous, there is support for the contention
308. See supra notes 34, 143-51 and accompanying text.
309. See supra notes 265-68 and accompanying text.
310. See supra notes 265-68 and accompanying text.
311. Bayer, 301 F.3d at 1315 (quoting 35 U.S.C. § 112 (1994)) (alteration in
original).
312. See supra notes 135-41 and accompanying text.
313. See supra notes 135-37 and accompanying text.
314. See supra notes 135-41 and accompanying text.
315. See supra notes 81-84 and accompanying text.
316. See supra notes 81-84 and accompanying text.
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that they need not apply only to the claimed invention. There
is no direct language in 35 U.S.C. § 112, ¶ 1, which explicitly
refers to the “claimed invention.” This statute refers only to
“the best mode of carrying out the invention.”317 Further, there
is no legislative history that mandates the restriction of § 112
to the claimed invention.318
Therefore, Bayer Corp. may have violated the best mode
requirement under 35 U.S.C. § 112, ¶ 1, regardless of whether
the Klauke compound or 6-FQA synthesis were or were not
undisclosed
preferred
embodiments
or
undisclosed
intermediates which materially affected the production of
Cipro. According to the text of § 112 and the legislative history
of the Patent Act, Bayer is required to disclose any preferred
method of producing Cipro without regard to its remoteness to
the claimed invention.
F. THE IMPACT OF ELI LILLY ON BAYER
Novel subject matter alone may require disclosure. The
facts of Eli Lilly are similar to those of Bayer.319 The inventor
in Eli Lilly disclosed the claimed invention, Prozac, but did not
disclose the inventor’s preferred method for synthesizing the
starting material needed to make Prozac.320 The Federal
Circuit held that any best mode involving novel subject matter
must be disclosed even if the novel subject matter is
unclaimed321 and held, in this case, that the unclaimed subject
matter was not novel, because it was commercially available
from more than one supplier.322
In Bayer, however, the starting materials for the synthesis
of Cipro were not commercially available.323 In fact, the Klauke
compound had to be synthesized by another scientist at Bayer
because Dr. Grohe was having difficulty synthesizing a
precursor to 6-FQA.324 If the Klauke compound had been
commercially available, Dr. Grohe most likely would have been
able to obtain it with more ease than actually occurred.
Therefore, since the two intermediates of Cipro were novel
317.
318.
319.
320.
321.
322.
323.
324.

35 U.S.C. § 112, ¶ 1.
See supra notes 47-61 and accompanying text.
See supra notes 163-70 and accompanying text.
See supra note 165 and accompanying text.
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See Bayer, 301 F.3d at 1310.
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under the Federal Circuit’s analysis in Eli Lilly, they were
required to be disclosed in the specification in order to comply
with the best mode requirement of 35 U.S.C. § 112, ¶1.
G. THE FEDERAL CIRCUIT’S INTERPRETATION OF THE BEST
MODE REQUIREMENT IN BAYER COMPARED TO THE UNITED
STATES PATENT AND TRADEMARK OFFICE’S INTERPRETATION OF
35 U.S.C. § 112, ¶ 1.
The USPTO’s interpretation of the best mode requirement
is quite similar to the Federal Circuit’s interpretation of the
best mode requirement.325 However, the USPTO expressly
recognizes that if the patent applicant develops specific
techniques that he or she recognizes as the best mode of
carrying out the invention, these must be disclosed in the
specification under the patentee’s obligation to the public to
disclose this preferred technique.326
Therefore, under the USPTO guidelines, Bayer Corp would
likely be required to disclose the Klauke compound and
synthetic route of 6-FQA in the ‘560 patent, since these
intermediates were developed by Dr. Grohe as specific
techniques to synthesize Cipro.
IV. CONCLUSION
In Bayer v. Schein, the Federal Circuit held that a
pharmaceutical company did not violate the best mode
requirement of 35 U.S.C. § 112, ¶ 1, when it failed to disclose
two intermediates in the synthesis of Cipro. The court relied
on past precedent to conclude that unclaimed subject matter
need only be disclosed for best mode purposes when it is a
concealed preferred embodiment of the claimed invention or
when it materially affects the making or using of the claimed
invention.
The Federal Circuit held that the two
intermediates, the Klauke compound and the synthetic route of
6-FQA, both unclaimed, were neither a preferred embodiment
nor did they materially affect the claimed invention, Cipro.
A closer analysis of the facts of precedent cases suggests
that the Federal Circuit erred in its holding. As analogized to
Spectra-Physics, Dana, Great Northern, and Nobelpharma, the
two intermediates in question in Bayer do materially affect the
making or using of Cipro. Further, like the invention in
325. See supra notes 175-83 and accompanying text.
326. See supra note 178 and accompanying text.
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Northern Telecom, they are both preferred embodiments of the
claimed invention. Analysis of Federal Circuit precedent leads
to these two conclusions. Additionally, other Federal Circuit
precedent, and USPTO rules, mandate the disclosure of the
Klauke compound and 6-FQA under 35 U.S.C. § 112, ¶ 1.
Finally, there is good social policy behind the best mode
requirement of disclosure of all necessary and important
subject matter. For these reasons, the public should be given
the chance to know how to synthesize Cipro from the Klauke
compound and the synthesis of 6-FQA.

